WILLOW BIOSCIENCES INC - CANSF STOCK NEWS

Willow Biosciences (TSX: WLLW, OTCQB: CANSF) has partnered with a global ingredient manufacturer to develop, scale, and commercialize a high-value ingredient from its internal portfolio. The collaboration includes R&D payments of up to $1.3 million and a 15-year tiered profit share arrangement. The 12-month research program targets a $1 billion global market segment currently dominated by chemically synthesized products. Willow aims to develop a high-purity, sustainable, bio-identical natural ingredient expected to be more cost-effective than chemical alternatives. The partner will handle regulatory compliance, manufacturing, and marketing responsibilities.

Willow Biosciences (TSX: WLLW; OTCQB: CANSF) has announced a second collaboration with a leading Active Pharmaceutical Ingredient (API) manufacturer. This new program aims to develop an optimized enzyme for large-scale manufacturing of a high-volume API used in a therapeutic with a global market exceeding $1 billion. The development phase is expected to last about six months, with potential milestone payments achievable by 2025. This marks Willow's 4th commercial agreement this year with potential milestone payments as early as next year. The collaboration builds on the success of their first program announced in January 2024, where Willow has already met certain development goals.

Willow Biosciences Inc. (TSX: WLLW; OTCQB: CANSF) has signed a commercial license and royalty agreement with Kalsec, Inc., a leading global producer of natural ingredients for the food and beverage industry. The agreement covers the use of Willow's technology for scaling and manufacturing a natural ingredient for savory food applications. Willow anticipates receiving milestone payments for the first pilot and industrial batches, followed by tiered royalty payments on net worldwide sales after launch.

The collaboration targets an existing $200M global market segment. Willow expects the research and development phase to be completed in 2024, with regulatory and scale-up work continuing into 2025. This agreement marks another successful transition of Willow's research program to commercial reality, highlighting the company's commitment to delivering safer and more sustainable natural products to consumers.

Willow Biosciences (TSX: WLLW; OTCQB: CANSF) reported record Q2 2024 revenue of $1.0 million, a 600% increase year-over-year. The company signed a strategic partnership with Laurus Labs to develop biobased processes for seven high-value APIs, expecting $4.0 million in guaranteed R&D payments in the first year. Willow anticipates over $4 million in revenue for 2024 from existing programs. The company also closed a private placement raising $1,639,737 and initiated a new feasibility study for bioactive pesticides production. With strengthened AI and business development capabilities, Willow continues to focus on revenue growth and cost reduction.

Willow Biosciences has announced a significant partnership with Laurus Labs to develop and manufacture active pharmaceutical ingredients (APIs), expecting $4 million in guaranteed R&D payments in the first year and annual royalties upon commercialization. The company projects revenue of over $1 million for Q2 and $3.5 million for 2024. Willow has also ventured into biopesticides, securing a proof-of-concept agreement with a biotech firm. Additional appointments include Dr. Richard Fox as Senior Advisor for AI Platform Technologies and Mr. Gregory Rocklin for Business and Corporate Development. The company has recently secured its first patent and plans to file five more in 2024. Willow aims to reduce its monthly burn rate and is optimistic about signing 2-3 new programs by year-end.

Willow Biosciences has announced a major partnership with Laurus Labs to develop and license multiple pharmaceutical ingredients. This strategic alliance grants Laurus access to Willow's AI-driven bioengineering platform, targeting seven high-value APIs, including corticosteroids. This partnership is Willow's largest to date, projected to generate significant annual revenues, with $4 million guaranteed in the first year for research and development. Willow's technology will help Laurus produce more sustainable and cost-effective APIs. Both companies anticipate commercial manufacturing to begin in 2025.

Willow Biosciences Inc. reported its first quarter 2024 financial results, showcasing reduced costs and progress in commercial expansion. The company continues to advance its corticosteroid production platform and expects to sign a large strategic partnership in Q2 2024. Willow signed new program agreements, advanced three programs, and aims to double its 2024 revenues. Financially, the company reduced cash burn by 53% compared to the previous year, ending the quarter with $1.6 million in cash.

Willow Biosciences Inc. reports a record revenue of $1.2 million in 2023, representing a 43% growth over 2022. The company completed a reorganization, moved all lab operations to Sunnyvale, California, and signed four new partnerships positioning it for growth in 2024. Willow's financial results show a net loss of $13.0 million in 2023, with cash and cash equivalents at $3.1 million as of December 31, 2023. The company anticipates significant revenue growth in 2024 with the transition of R&D programs to commercial revenue and the execution of partnership agreements on corticosteroid programs.

Willow Biosciences Inc. secures a second strategic investment from Kalsec Inc. for the development of natural food ingredients, achieving a significant milestone. The investment will aid in commercializing the company's product pipeline and supporting general corporate activities.